Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SYR-472 Open-label Study

Trial Profile

SYR-472 Open-label Study

Phase of Trial: Phase III

Latest Information Update: 23 May 2016

At a glance

  • Drugs Trelagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 26 Mar 2015 According to Takeda Pharmaceuticals media release, based on the results of this and other phase III trials ( see profile 219690 and 206116), Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application of Zafatek (trelagliptin succinate).
    • 01 Aug 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top